---
title: "The Illumina GRAIL acquisition and divestment case"
layout: page
description: "How regulatory opposition, activist intervention, and shareholder litigation followed Illumina’s decision to close the GRAIL acquisition under review, and how governance reset and divestiture unfolded."
date: 2026-01-11
category: founder-stories

tags:
  - governance
  - antitrust
  - activism
  - mergers
  - sequencing
  - cancer-screening

entities:
  people:
    - Francis deSouza
    - Carl Icahn
    - Andrew Teno
    - Jacob Thaysen
    - Charles Dadswell
    - Stephen P. MacMillan
  organisations:
    - Illumina
    - GRAIL
    - Icahn Partners
    - Federal Trade Commission
    - European Commission
    - U.S. Securities and Exchange Commission
  projects:
    - Illumina–GRAIL acquisition
    - GRAIL spin-off (Nasdaq GRAL)
  formats:
    - SEC Form 10
    - proxy materials
    - administrative litigation
---

How regulatory opposition, activist intervention, and shareholder litigation followed Illumina’s decision to close the GRAIL acquisition under review, and how governance reset and divestiture unfolded.

The Illumina–GRAIL episode is often framed as a failed acquisition, but the starting point deserves nuance. GRAIL itself originated as an Illumina spin-out in 2015–2016, created to pursue blood-based cancer detection using sequencing technology that Illumina had enabled. From a purely strategic perspective, reacquiring a former subsidiary developing a potentially transformative clinical application was not irrational. Absent antitrust constraints, many observers viewed reintegration as a logical long-term platform move.

The conflict emerged not from the basic idea of recombining platform and application, but from regulatory concerns about vertical integration and, critically, from the decision to close the transaction while regulatory reviews were still active. Timing and regulatory risk assessment, rather than acquisition logic alone, became central to the later governance crisis.

A second nuance concerns activist investor Carl Icahn. Public discussion often focuses on personality, but in practice activism functions as a governance mechanism within public markets. Illumina represents only a small episode within Icahn’s long career, and his involvement followed visible shareholder losses and regulatory setbacks rather than preceding them. In this case, activism acted less as personal intervention and more as a governance mechanism pushing leadership change, though one of Icahn’s three nominees ultimately joined the board.

Finally, the broader backdrop matters. 
Illumina remains a central infrastructure company in genomics, enabling modern research and diagnostics through large-scale, low-cost sequencing. Yet for many users sequencing solves only the first step, while converting data into actionable conclusions still requires complex downstream interpretation. The larger opportunity lies in end-to-end genomic workflows rather than sequencing alone, analogous to selling an iPod without a music ecosystem. Recent years, however, saw management attention drawn into merger and regulatory conflicts rather than advancing these adoption challenges, leaving expectations high but execution unfinished.

Against that backdrop, the acquisition became one of the most consequential governance episodes in genomics infrastructure. Illumina supplied sequencing instruments and consumables to companies developing clinical tests, including firms competing with GRAIL. Owning a downstream competitor created concerns that Illumina could influence competition by controlling upstream access.

The controversy escalated when Illumina chose to complete the acquisition while antitrust investigations in both the United States and European Union were still active. Regulators responded with interim measures, litigation, fines, and eventually divestiture orders. By the time separation became unavoidable, shareholder focus shifted from strategy to governance and accountability.

This episode demonstrates how markets, regulators, and shareholders apply corrective pressure when strategic risk decisions collide with regulatory authority.

| Item | Detail |
| --- | --- |
| Case focus | Governance conflict and activism following Illumina’s acquisition and forced divestment of GRAIL |
| Core bottleneck | Vertical integration risk under simultaneous US and EU antitrust enforcement |
| Key actors | Illumina board and leadership; Icahn Partners; FTC; European Commission; shareholders |
| Named individuals | Francis deSouza; Carl Icahn; Andrew Teno; Charles Dadswell; Jacob Thaysen; Stephen P. MacMillan |
| Primary mechanisms | Proxy contest, regulatory enforcement, shareholder litigation, corporate separation filings |
| First decisive turning point | Illumina closes acquisition under regulatory review (August 2021) |
| Key penalty disclosed | European Commission fine of €432 million (July 2023) |
| Structural remedy outcome | GRAIL spun off as Nasdaq: GRAL (June 24, 2024); Illumina retains minority stake |
| Pricing model | Not product pricing; costs include penalties, legal expenses, and transaction costs |
| Distribution mechanism | Proxy votes, SEC filings, regulator decisions, public disclosures |
| Governance maintenance | Board refresh, leadership turnover, compliance oversight |
| Current status | Illumina refocused on sequencing platform; GRAIL operates independently |
| Persistent lesson | Vertical expansion by platform providers carries governance and regulatory risk |

## Situation and tension

Before the deal, Illumina functioned as infrastructure for genomics. Its sequencing platforms powered research labs, hospitals, and diagnostic developers. GRAIL operated downstream, developing blood-based multi-cancer detection tests built on Illumina sequencing.

Vertical mergers are not automatically prohibited, but they create two risks regulators examine closely. First, competitors fear subtle disadvantages in access or pricing. Second, regulators worry that ownership changes incentives, encouraging discrimination against rivals.

Illumina announced its plan to acquire GRAIL in September 2020. The FTC challenged the deal in March 2021. The European Commission opened an investigation in July 2021. Despite both actions, Illumina completed the acquisition in August 2021.

This shifted the conflict from theoretical competition concerns to compliance and enforcement reality.

## Operational consequences of closing under review

After closing, Illumina faced operational constraints that limited the value of the acquisition:

• hold-separate requirements prevented integration  
• compliance monitoring restricted information sharing  
• integration attempts risked further penalties  
• customers competing with GRAIL faced uncertainty about supplier neutrality  

Ownership costs remained while operational benefits were constrained.

## Activist intervention and governance reset

Carl Icahn’s investment group entered after the regulatory conflict became clear. The activist campaign argued the board misjudged regulatory risk and capital allocation.

Icahn nominated Andrew Teno, Jesse Lynn, and Vincent Intrieri to Illumina’s board. Only Teno was elected, but even a single seat signalled shareholder dissatisfaction and increased pressure for change.

Leadership turnover followed. CEO Francis deSouza resigned in June 2023. Charles Dadswell became interim CEO, and Jacob Thaysen was appointed CEO later that year. Stephen P. MacMillan assumed the chair role during the governance reset.

These changes did not resolve regulatory actions directly but enabled execution of divestiture once outcomes became unavoidable.

## How activism spreads

Corporate activism propagates through mechanisms different from technical adoption:

• shareholder votes  
• proxy adviser recommendations  
• institutional investor positions  
• negotiated settlements  
• media scrutiny  
• parallel regulatory pressure  

By 2023, regulatory penalties and divestiture orders narrowed strategic options. Governance change allowed execution to replace resistance.

## Divestiture mechanics

Divestiture required corporate infrastructure, not scientific innovation.

Execution steps included:

• board approval of separation plans  
• filing SEC Form 10 registration statements  
• preparing audited carve-out financials  
• separating IT, contracts, governance, and operations  
• establishing independent capital structure  
• listing GRAIL publicly  

On June 24, 2024, GRAIL began trading independently on Nasdaq under ticker GRAL. Illumina retained a minority ownership stake.

Divestitures are operationally complex transactions requiring organisational separation across every system supporting the business.

## Case timeline

| Date | Actor | Action | Jurisdiction | Immediate consequence |
| --- | --- | --- | --- | --- |
| 2015–2016 | Illumina, GRAIL | GRAIL formed as spin-out | US | Upstream–downstream relationship established |
| Sep 2020 | Illumina | Announces acquisition of GRAIL | US/EU | Antitrust scrutiny begins |
| Mar 2021 | FTC | Files challenge to merger | US | Litigation begins |
| Jul 2021 | European Commission | Opens investigation | EU | Regulatory review escalates |
| Aug 18 2021 | Illumina | Closes acquisition | US/EU | Enforcement risk intensifies |
| Oct 2021 | European Commission | Orders hold-separate | EU | Integration restricted |
| Sep 2022 | FTC ALJ | Rules against FTC challenge | US | Appeal path continues |
| Apr 2023 | FTC | Orders divestiture | US | Structural remedy mandated |
| Jun 2023 | Illumina | CEO deSouza resigns | US | Governance reset begins |
| Jul 2023 | European Commission | Imposes €432M fine | EU | Financial penalty increases pressure |
| Jun 2023 | Shareholders | Icahn nominee Andrew Teno elected | US | Board pressure intensifies |
| Oct 2023 | European Commission | Orders divestment | EU | Separation becomes mandatory |
| Apr–May 2024 | Illumina, SEC | Form 10 filed | US | Spin-off preparation |
| Jun 24 2024 | Illumina, GRAIL | Spin-off completed | US | Companies separated |

## Decision to consequence map

| Decision | Regulator response | Operational effect | Governance effect |
| --- | --- | --- | --- |
| Close under active review | Interim measures and fines | Integration blocked | Shareholder dissatisfaction |
| Continue contesting regulators | Divestiture orders | Resource drain | Activism gains support |
| Leadership reset | Not regulatory action | Enables execution | CEO and board turnover |
| Execute spin-off | Regulatory compliance | Separation achieved | Crisis phase ends |

## Litigation as accountability mechanism

Shareholder litigation functions as a slower but formal accountability mechanism after strategic reversals. Such cases focus less on business outcomes and more on whether boards fulfilled duties of care and disclosure during decision-making.

## Consequence and legacy

The lasting output of this episode is governance learning for platform companies. When a platform supplier enters customer markets, trust and regulatory tolerance narrow. Timing decisions become as consequential as technological decisions.

Operationally, Illumina gained experience executing a full corporate separation under regulatory pressure, capabilities that persist beyond this episode.

The durable lesson is that the cost of strategic error is not only financial penalties but years of constrained operation, leadership change, and forced reversal under public scrutiny.

## Links

- https://en.wikipedia.org/wiki/Illumina,_Inc.
- https://en.wikipedia.org/wiki/Grail_(company)
- https://grail.com/about-us/
- https://grail.com/our-history/
- https://www.illumina.com/science/technology/next-generation-sequencing/illumina-sequencing-history.html
- https://www.ftc.gov/
- https://ec.europa.eu/

